(Q36103890)

12 August 2017

1 reference

title

Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias (English)

1 reference

12 August 2017

0 references

1 reference

José L Molinuevo

1

1 reference

12 August 2017

Albert Lladó

series ordinal

2

1 reference

12 August 2017

Lorena Rami

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

American Journal of Alzheimer's Disease & Other Dementias

12 August 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

12 August 2017

volume

20

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

77-85

1 reference

Alzheimer Disease in the US Population

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Memory systems in the brain and localization of a memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

The Biochemistry of Memory: A New and Specific Hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

beta-Amyloid peptide fragment 25-35 potentiates the calcium-dependent release of excitatory amino acids from depolarized hippocampal slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Modulation of tau neuronal expression induced by NMDA, non-NMDA and metabotropic glutamate receptor agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

N-Methyl-D-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Evaluation of memantine for neuroprotection in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Effect of memantine on the levels of glial cells, neuropeptides, and peptide-degrading enzymes in rat brain regions of ibotenic acid-treated alzheimer's disease model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Memantine enhances autonomy in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Memantine in vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F153331750502000206

10.1177/153331750502000206

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference